MX2023002948A - Métodos y composiciones para modular la inmunidad mediada por cadena beta. - Google Patents

Métodos y composiciones para modular la inmunidad mediada por cadena beta.

Info

Publication number
MX2023002948A
MX2023002948A MX2023002948A MX2023002948A MX2023002948A MX 2023002948 A MX2023002948 A MX 2023002948A MX 2023002948 A MX2023002948 A MX 2023002948A MX 2023002948 A MX2023002948 A MX 2023002948A MX 2023002948 A MX2023002948 A MX 2023002948A
Authority
MX
Mexico
Prior art keywords
methods
compositions
beta chain
mediated immunity
antibodies
Prior art date
Application number
MX2023002948A
Other languages
English (en)
Inventor
Sanjaya Singh
Rajkumar Ganesan
Iqbal S Grewal
Michael Riis Hansen
Original Assignee
Janssen Biotech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Biotech Inc filed Critical Janssen Biotech Inc
Publication of MX2023002948A publication Critical patent/MX2023002948A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464402—Receptors, cell surface antigens or cell surface determinants
    • A61K39/464416—Receptors for cytokines
    • A61K39/464417—Receptors for tumor necrosis factors [TNF], e.g. lymphotoxin receptor [LTR], CD30
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464454—Enzymes
    • A61K39/464458—Proteinases
    • A61K39/46446—Serine proteases, e.g. kallikrein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Abstract

Se describen anticuerpos anti-Vß17 o fragmentos de unión al antígeno de estos; también se describen ácidos nucleicos que codifican los anticuerpos, composiciones que comprenden los anticuerpos, métodos para producir los anticuerpos, y métodos para usar los anticuerpos para tratar o prevenir enfermedades.
MX2023002948A 2020-09-11 2021-09-10 Métodos y composiciones para modular la inmunidad mediada por cadena beta. MX2023002948A (es)

Applications Claiming Priority (13)

Application Number Priority Date Filing Date Title
US202063077397P 2020-09-11 2020-09-11
US202063077387P 2020-09-11 2020-09-11
US202063077314P 2020-09-11 2020-09-11
US202063104265P 2020-10-22 2020-10-22
US202063104220P 2020-10-22 2020-10-22
US202063104247P 2020-10-22 2020-10-22
US202163142944P 2021-01-28 2021-01-28
US202163142940P 2021-01-28 2021-01-28
US202163142930P 2021-01-28 2021-01-28
US202163165053P 2021-03-23 2021-03-23
US202163176112P 2021-04-16 2021-04-16
US202163237972P 2021-08-27 2021-08-27
PCT/US2021/049761 WO2022056192A1 (en) 2020-09-11 2021-09-10 Methods and compositions for modulating beta chain mediated immunity

Publications (1)

Publication Number Publication Date
MX2023002948A true MX2023002948A (es) 2023-05-22

Family

ID=80629876

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023002948A MX2023002948A (es) 2020-09-11 2021-09-10 Métodos y composiciones para modular la inmunidad mediada por cadena beta.

Country Status (11)

Country Link
US (1) US11965024B2 (es)
EP (1) EP4211170A1 (es)
JP (1) JP2023540796A (es)
KR (1) KR20230084508A (es)
AU (1) AU2021339754A1 (es)
CA (1) CA3194968A1 (es)
IL (1) IL301254A (es)
MX (1) MX2023002948A (es)
TW (1) TW202227495A (es)
UY (1) UY39415A (es)
WO (1) WO2022056192A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112023016121A2 (pt) * 2021-02-16 2023-11-28 Janssen Pharmaceutica Nv Anticorpo triespecífico que direciona bcma, gprc5d e cd3
CN114940710B (zh) * 2022-06-07 2023-09-26 恺佧生物科技(上海)有限公司 一种提高重组人psma蛋白表达的方法

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6413516B1 (en) * 1989-03-21 2002-07-02 The Immune Response Corporation Peptides and methods against psoriasis
US6221352B1 (en) * 1989-03-21 2001-04-24 The Immune Response Corporation Method of preventing the proliferation of Vβ14 or Vβ17-Expressing T cells
US6084087A (en) 1991-09-27 2000-07-04 New York Society For The Ruptured And Crippled Maintaing The Hospital For Special Surgery DNA encoding conserved T-cell receptor sequences
ATE462004T1 (de) 1997-09-16 2010-04-15 Centocor Inc Methoden zur kompletten chemischen synthese und zusammensetzung von genen und genomen
US6670127B2 (en) 1997-09-16 2003-12-30 Egea Biosciences, Inc. Method for assembly of a polynucleotide encoding a target polypeptide
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
EP1789446A2 (en) 2004-09-02 2007-05-30 Genentech, Inc. Heteromultimeric molecules
ES2592271T3 (es) 2005-03-31 2016-11-29 Chugai Seiyaku Kabushiki Kaisha Métodos de producción de polipéptidos mediante la regulación de la asociación de los polipéptidos
US7585960B2 (en) 2005-05-11 2009-09-08 Theramab Gmbh Nucleic acids encoding superagonistic anti-CD28 antibodies
DE102005028778A1 (de) 2005-06-22 2006-12-28 SUNJÜT Deutschland GmbH Mehrlagige Folie mit einer Barriere- und einer antistatischen Lage
JP2009541275A (ja) 2006-06-22 2009-11-26 ノボ・ノルデイスク・エー／エス 二重特異性抗体の生産
US20110097339A1 (en) 2008-07-18 2011-04-28 Domantis Limited Compositions monovalent for CD28 binding and methods of use
UA109633C2 (uk) 2008-12-09 2015-09-25 Антитіло людини проти тканинного фактора
JP2012525149A (ja) 2009-04-27 2012-10-22 オンコメッド ファーマシューティカルズ インコーポレイテッド ヘテロ多量体分子を作製するための方法
JO3182B1 (ar) 2009-07-29 2018-03-08 Regeneron Pharma مضادات حيوية بشرية عالية الالفة مع تولد الاوعية البشرية - 2
AU2011244282A1 (en) 2010-04-20 2012-11-15 Genmab A/S Heterodimeric antibody Fc-containing proteins and methods for production thereof
RS56599B1 (sr) 2010-06-15 2018-02-28 Genmab As Konjugati humanog antitela sa lekom protiv tkivnog faktora
AU2011325833C1 (en) 2010-11-05 2017-07-13 Zymeworks Bc Inc. Stable heterodimeric antibody design with mutations in the Fc domain
KR102052774B1 (ko) 2011-11-04 2019-12-04 자임워크스 인코포레이티드 Ｆｃ 도메인 내의 돌연변이를 갖는 안정한 이종이합체 항체 설계
EP3215538A4 (en) 2014-11-07 2018-07-04 Igenica Biotherapeutics, Inc. Anti-cd39 antibodies and uses thereof
AR104250A1 (es) 2015-04-16 2017-07-05 Eisai R&D Man Co Ltd Anticuerpo anti-notch4 humano
JO3711B1 (ar) 2015-07-13 2021-01-31 H Lundbeck As أجسام مضادة محددة لبروتين تاو وطرق استعمالها
WO2017058944A1 (en) 2015-09-29 2017-04-06 Amgen Inc. Asgr inhibitors
TWI790206B (zh) 2016-07-18 2023-01-21 法商賽諾菲公司 特異性結合至ｃｄ３和ｃｄ１２３的雙特異性抗體樣結合蛋白
CN111344303A (zh) 2017-06-01 2020-06-26 Xencor股份有限公司 结合cd123和cd3的双特异性抗体
US20230158141A1 (en) 2017-11-08 2023-05-25 Yafei Shanghai Biolog Medicine Science & Technolog Co., Ltd Conjugates of Biomolecule and Use Thereof
BR112020025764A2 (pt) 2018-06-19 2021-05-11 Biontech Us Inc. neoantígenos e usos dos mesmos
CA3105448A1 (en) 2018-07-03 2020-01-09 Elstar Therapeutics, Inc. Anti-tcr antibody molecules and uses thereof
CA3125345A1 (en) 2019-01-04 2020-07-09 Marengo Therapeutics, Inc. Anti-tcr antibody molecules and uses thereof
MA55305A (fr) 2019-03-11 2022-01-19 Janssen Biotech Inc Anticorps bispécifiques anti-v béta 17/anti-cd123
AU2020298324A1 (en) 2019-06-21 2022-01-27 Single Cell Technology, Inc. Anti-TIGIT antibodies
CA3156818A1 (en) 2019-10-03 2021-04-08 Janssen Biotech, Inc. Methods for producing biotherapeutics with increased stability by sequence optimization
JP2023540799A (ja) 2020-09-11 2023-09-26 ヤンセン バイオテツク，インコーポレーテツド 多重特異性免疫標的化分子及びその使用

Also Published As

Publication number Publication date
KR20230084508A (ko) 2023-06-13
US11965024B2 (en) 2024-04-23
WO2022056192A9 (en) 2023-02-16
AU2021339754A1 (en) 2023-05-25
TW202227495A (zh) 2022-07-16
JP2023540796A (ja) 2023-09-26
WO2022056192A1 (en) 2022-03-17
IL301254A (en) 2023-05-01
EP4211170A1 (en) 2023-07-19
CA3194968A1 (en) 2022-03-17
UY39415A (es) 2022-03-31
US20220089731A1 (en) 2022-03-24

Similar Documents

Publication Publication Date Title
MX2020009366A (es) Anticuerpos anti-cd73 y usos de los mismos.
ZA202004730B (en) Anti-claudin 18.2 antibodies and uses thereof
PH12020552010A1 (en) Anti-cd33 antibodies, anti-cd33/anti-cd3 bispecific antibodies and uses thereof
PH12019501973A1 (en) Anti-phf-tau antibodies and uses thereof
MX2020008075A (es) Anticuerpos anti-ctla4 y métodos para elaborarlos y usarlos.
MX2022009306A (es) Loseta de nucleo de espuma densificada (dfc) con linea de anticuerpos de dominio individual de cd28 y constructos multivalentes y multiespecíficas de los mismos.
JOP20190187A1 (ar) مترافقات عقار جسم مضاد لـ ccr7
MX2023002948A (es) Métodos y composiciones para modular la inmunidad mediada por cadena beta.
MX2020011914A (es) Anticuerpos anti-dll3 y usos de los mismos.
AU2019415848A8 (en) Claudin18.2 binding moieties and uses thereof
WO2020082209A8 (zh) 抗cldn18.2抗体及其用途
MX2020009522A (es) Anticuerpos anti-folato del receptor 1 y usos de los mismos.
MX2023002945A (es) Moléculas multiespecíficas con direccionamiento inmunitario y usos de estas.
MX2022012628A (es) Anticuerpos anti-phf-tau y usos de estos.
MX2022010664A (es) Materiales y métodos para modular una respuesta inmunitaria.
MX2021006362A (es) Anticuerpos de dominio simple contra cll-1.
MX2021006930A (es) Construcciones de proteínas de fusión para enfermedades asociadas al complemento.
MX2020001287A (es) Receptor de linfocitos t (tcrs) especificos de braf y usos de los mismos.
MX2021013532A (es) Materiales y metodos para modular la inmunidad mediada por celulas t.
PH12020500662A1 (en) Anti-pfrh5 antibodies and antigen-binding fragments thereof
ZA202110285B (en) Antibodies and methods of use
MX2022003523A (es) Proteinas de union a antigenos.
MX2022015966A (es) Anticuerpos y metodos para tratar enfermedades asociadas a claudina.
MX2022007513A (es) Anticuerpos biespecificos con cisteinas intercatenarias apareadas alternativamente y sus usos.
EA202193035A1 (ru) Материалы и способы для модуляции иммунитета, опосредованного т-клетками